Claims for Patent: 8,232,294

Summary for Patent: 8,232,294

Title:	Amino ester derivatives, sailts thereof and methods of use
Abstract:	The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Inventor(s):	Xi; Ning (Thousand Oaks, CA)
Assignee:	Xi; Ning (Newbury Park, CA) Sunshine Lake Pharma Co., Ltd. (Northern Industrial Area, Songshan Lake, Dongguan, Guangdong, CN)
Application Number:	12/728,153
Patent Claims:	1. A compound of the Formula (I): ##STR00166## or a recemic mixture, a diastereoisomer, an enantiomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein: each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently H, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)--NR.sup.11R.sup.11a, R.sup.11R.sup.11aN--O.sub.2S--, R.sup.11O.sub.2S--, R.sup.11aR.sup.11N-alkyl, R.sup.11O-alkyl, aliphatic, haloaliphatic, arylaliphatic, heterocyclyl aliphatic, cycloalkyl aliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl, with the proviso that R.sup.1 and R.sup.2, together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered heterocyclic ring; and R.sup.3 and R.sup.4, together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring; each of Y.sub.1 and Y.sub.2 is independently a divalent group derived from aliphatic-C(.dbd.O)--, aliphatic-C(.dbd.O)O--, aliphatic-C(.dbd.O)NR.sup.11--, --R.sup.11N--O.sub.2S-aliphatic, --O.sub.2S--, --R.sup.11N-aliphatic, --S(.dbd.O)-aliphatic, or --R.sup.11N--C(.dbd.O)-aliphatic; or fused bicyclylalkylene, fused hetero-bicyclyl alkylene, spiro bicyclylalkylene, spiro heterobicyclyl alkylene, arylalkylene, heteroarylalkylene, alkylene; haloalkylene, heterocyclylene, carbocyclylene, heterocyclylalkylene, carbocyclylalkylene, fused bicyclylene, fused heterobicyclylene, spiro bicyclylene, spiro heterobicyclylene, arylene, or heteroarylene; W is O, N--R.sup.11 or (CR.sup.12R.sup.12a)m; m is 0, 1, 2 or 3; Q is: ##STR00167## ##STR00168## wherein U is CR.sup.12 or N; each of R.sup.5, R.sup.6 is independently H, F, Cl, Br, I, --CN, hydroxyl, R.sup.11aR.sup.11N--, --C(.dbd.O)--R.sup.11, --C(.dbd.O)--OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)OR.sup.11, --NR.sup.11C--(.dbd.O)NR.sup.11R.sup.11a, --NR.sup.11C(.dbd.O)OR.sup.11a, --NR.sup.11C(.dbd.O)--R.sup.11a, R.sup.11R.sup.11aN--O.sub.2S--, R.sup.11O.sub.2S--, R.sup.11O.sub.2S--R.sup.11aN--, R.sup.11aR.sup.11N-alkyl, R.sup.11(S.dbd.O)-alkyl, R.sup.11R.sup.11aN--(C.dbd.O)-alkyl, R.sup.11aR.sup.11N-alkoxy, R.sup.11(S.dbd.O)-alkoxy, R.sup.11R.sup.11aN--(C.dbd.O)-alkoxy, aliphatic, alkoxy, hydroxyalkoxy, amino-alkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituthed haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxy-alkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxy-alkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused hetero-bicyclyl aminoalkoxy, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicycloxo-alkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclyl-aminoalkoxy, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic; R.sup.7 is one or more substituents independently selected at each occurrence from H, F, Cl, Br, I, --CN, hydroxyl, R.sup.11aR.sup.11N--, aliphatic, alkoxy, haloalkyl, hetero-cyclyl, heterocyclylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, and heterocyclylalkoxy; each of R.sup.8, R.sup.9 and R.sup.10 is independently H, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)--NR.sup.11R.sup.11a, R.sup.11R.sup.11aN--O.sub.2S--, R.sup.11O.sub.2S--, R.sup.11aR.sup.11N-alkyl, R.sup.11(S.dbd.O)-alkyl, R.sup.11R.sup.11aN(C.dbd.O)-alkyl, aliphatic, hydroxyalkyl, hydroxy-substituted aminoalkyl, haloalkyl, amino-substituthed haloalkyl, alkylamino haloalkyl, hydroxy-substituted haloalkyl, alkoxyalkyl, arylalkyl, heterocyclylalkyl, carbocyclylalkyl, heterocyclyl-hydroxyalkyl, carbocyclyl-hydroxyalkyl, aryl-hydroxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, carbocyclyloxy-alkyl, heterocyclylyl, cycloalkylyl, (heterocyclo)hydroxy-alkyl, azidoalkyl, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxoalkyl, fused heterobicycloxoalkyl, fused bicyclyl aminoalkyl, fused heterobicyclyl aminoalkyl, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxoalkyl, spiro hetero-bicycloxoalkyl, spiro bicyclylaminoalkyl, spiro heterobicyclylaminoalkyl, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic; each of R.sup.11 and R.sup.11a is independently H, aliphatic, haloaliphatic, hydroxy-aliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryl-aliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl, with th eproviso that where R.sup.11 and R.sup.11a are bonded to the same nitrogen atom, R.sup.11 and R.sup.11a, together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, comprising a spiro ring or a bicyclic ring; and each of R.sup.12 and R.sup.12a is independently H, F, Cl, Br, I, --CN, hydroxyl, --NR.sup.11aR.sup.11, --OC(.dbd.O)R.sup.11, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)OR.sup.11, --NR.sup.11C(.dbd.O)NR.sup.11R.sup.11a, --NR.sup.11C(.dbd.O)OR.sup.11a, --NR.sup.11--C(.dbd.O)--R.sup.11a, R.sup.11R.sup.11aN--O.sub.2S--, R.sup.11O.sub.2S--, R.sup.11O.sub.2S--N(R.sup.11a)--, alkoxy, cycloalkoxy, heterocycloalkoxy, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclyl-aliphatic, cycloalkylaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl, with the proviso that where R.sup.12 and R.sup.12a are bonded to the same carbon atom, R.sup.12 and R.sup.12a, together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring. 2. The compound according to claim 1, wherein the pharmaceutically acceptable salt is a salt with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, malic acid, 2-hydroxypropanic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, glucuronic acid, galacturonic acid, citric acid, tartaric acid, aspartic acid, glutamic acid, benzoic acid, cinnamic acid, p-toluenesulfonic acid, benzenesulfonic acid, mthanesulfonic acid, ethanesulfonic acid, trifluoromthanesulfonic acid, or a combination thereof. 3. The compound according to claim 1, wherein the .alpha.-amino acetyl group defined by R.sup.1, R.sup.2, R.sup.3 and R.sup.4 of Formula (I) is derived from a naturally occurring and commercially available .alpha.-amino acid or an optically isomer thereof. 4. The compound according to claim 3, wherein the natural and commercially available .alpha.-amino acid is isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartate, glutamate, glutamine, proline, serine, para-tyrosine, arginine, histidine, cysteine, glycine, sarcosine, N,N-dimethyl glycine, homoserine, norvaline, norleucine, ornithine, homocysteine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine or hydroxyproline. 5. The compound according to claim 4, wherein the natural .alpha.-amino acid is isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, asparagine, aspartate, glutamate, glutamine, proline, serine, tyrosine, arginine, or histidine, each of which has a S-configuration at the .alpha.-position. 6. The compound according to claim 4, wherein the natural and commercially available .alpha.-amino acid is the cysteine having a R-configuration at its .alpha.-position. 7. The compound according to claim 4, wherein the natural and commercially available .alpha.-amino acid is glycine, sarcosine or N,N-dimethyl glycine, each of which is a non-chiral compound. 8. The compound according to claim 1, wherein each of Y.sub.1 and Y.sub.2 is independently a divalent group derived from C.sub.1-6aliphatic-C(.dbd.O)--, C.sub.1-6aliphatic-C(.dbd.O)O--, C.sub.1-6aliphatic-C(.dbd.O)NR.sup.11--, --R.sup.11N--O.sub.2SC.sub.1-6aliphatic, --O.sub.2S--C.sub.1-6aliphatic, --R.sup.11NC.sub.1-6aliphatic, --S(.dbd.O)C.sub.1-6 aliphatic, or --R.sup.11N--C(.dbd.O)--C.sub.1-6aliphatic; or fused C.sub.6-10bicyclyl C.sub.1-6alkylene, fused C.sub.5-9 hetero-bicyclyl C.sub.1-6 alkylene, spiro C.sub.7-11bicyclyl C.sub.1-6 alkylene, spiro C.sub.6-10heterobicyclyl C.sub.1-6 alkylene, C.sub.1-6haloalkylene, C.sub.2-8heterocyclylene, C.sub.3-8carbocyclylene, C.sub.2-8heterocyclyl C.sub.1-6 alkylene, C.sub.3-8carbocyclyl C.sub.1-6alkylene, fused C.sub.6-10bicyclylene, fused C.sub.5-9heterobicyclyl-ene, spiro C.sub.7-11bicyclylene, or spiro C.sub.6-10heterobicyclylene; W is O, N--R.sup.11 or (CR.sup.12R.sup.12a)m; m is 0, 1 or 2; Q is: ##STR00169## ##STR00170## wherein U is CH or N; Each of R.sup.5 and R.sup.6 is independently H or methoxy; R.sup.7 is H or F; R.sup.10 is phenyl or fluorophenyl; Each of R.sup.11 and R.sup.11a is independently H, C.sub.1-3alkyl, C.sub.1-3haloalkyl, C.sub.1-3 hydroxy-alkyl, C.sub.1-3aminoalkyl, C.sub.1-3alkoxy C.sub.1-3alkyl, C.sub.1-3 alkylamino C.sub.1-3alkyl, C.sub.6-10aryl C.sub.1-3alkyl, C.sub.5-9heterocyclyl C.sub.1-3alkyl, C.sub.3-6cycloalkyl C.sub.1-3alkyl, C.sub.6-10aryl, C.sub.5-9heteroaryl, C.sub.2-5 hetero-cyclyl, or C.sub.3-6carbocyclyl, with the proviso that where R.sup.11 and R.sup.11a are bonded to the same nitrogen atom, R.sup.11 and R.sup.11a together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, comprising a spiro ring or a fused bicyclic ring; and Each of R.sup.12 and R.sup.12a is independently H, F, Cl, Br, I, hydroxyl, --NR.sup.11aR.sup.11, --OC(.dbd.O)R.sup.11, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)NR.sup.11R.sup.11a, --OC(.dbd.O)OR.sup.11, --NR.sup.11C(.dbd.O)NR.sup.11R.sup.11a, --NR.sup.11C(.dbd.O)OR.sup.11a, --NR.sup.11C(.dbd.O)--R.sup.11a, R.sup.11R.sup.11aN--O.sub.2S--, R.sup.11O.sub.2S--, R.sup.11R.sup.11aO.sub.2SN--, --CN, hydroxyl, C.sub.1-6alkoxy, C.sub.3-6cycloalkoxy, C.sub.2-5 hetero-cyclo C.sub.1-6alkoxy, C.sub.1-6aliphatic, C.sub.1-6haloaliphatic, hydroxy C.sub.1-6aliphatic, amino C.sub.1-6 aliphatic, C.sub.1-6alkoxy C.sub.1-6aliphatic, C.sub.1-6alkylamino C.sub.1-6aliphatic, C.sub.1-6alkylthio C.sub.1-6aliphatic, C.sub.6-10aryl C.sub.1-6aliphatic, C.sub.1-9 heteroaryl C.sub.1-6aliphatic, C.sub.2-5heterocyclyl C.sub.1-6 aliphatic, C.sub.3-6cycloalkyl C.sub.1-6aliphatic, C.sub.6-10aryl, C.sub.1-9heteroaryl, C.sub.2-5heterocyclyl, or C.sub.3-6 carbocyclyl, with the proviso that where R.sup.12 and R.sup.12a are bonded to the same carbon atom, R.sup.12 and R.sup.12a, together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring. 9. The compound according to claim 1, wherein Q is: ##STR00171## ##STR00172## ##STR00173## wherein each of R.sup.5 and R.sup.6 is independently H or OMe; Z is H or F. 10. The compound according to claim 1, wherein the substructure defined by Y.sub.1, Y.sub.2, W and Q is: ##STR00174## ##STR00175## wherein AA is an amino acetyl moiety defined by R.sup.1, R.sup.2, R.sup.3 and R.sup.4; X is H or OH; p is 0, 1, 2 or 3. 11. The compound of claim 1 having one of the following structures: ##STR00176## ##STR00177## ##STR00178## ##STR00179## ##STR00180## ##STR00181## ##STR00182## ##STR00183## ##STR00184## ##STR00185## ##STR00186## or a pharmacetical acceptable salt thereof. 12. A compound according to claim 1, wherein the compound has one of the following structures: ##STR00187## ##STR00188## ##STR00189## ##STR00190## ##STR00191## ##STR00192## ##STR00193## ##STR00194## ##STR00195## ##STR00196## ##STR00197## ##STR00198## ##STR00199## ##STR00200## ##STR00201## ##STR00202## 13. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 14. The pharmaceutical composition according to claim 13 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis, or a combination thereof. 15. The pharmaceutical composition according to claim 14, wherein the additional therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabin, cyclophosphamide, dexamethasone, etoposide, fluorouracil, imatinib mesylate, dasatinib, nilotinib, erlotinib, lapatinib, iressa, sorafenib, sunitinib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab (Bexxar), trabedectin, Avastin (bevacizumab), Herceptin (trastuzumab), Erbitux (cetuximab), Vectibix (panitumumab), or a combination thereof. 16. A method of managing, treating or lessening the severity of a proliferative disorder in a patient comprising administering to the patient the compound of claim 1. 17. A method of managing, treating or lessening the severity of a proliferative disorder in a patient comprising administering to the patient the pharmaceutical composition of claim 13. 18. The method according to claim 16, wherein the proliferative disorder is metastatic cancer, colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, thyroid cancer, cancer of the head and neck, prostate cancer, pancreatic cancer, cancer of the CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis or lung fibrosis. 19. The method according to claim 17, wherein the proliferative disorder is metastatic cancer, colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, thyroid cancer, cancer of the head and neck, prostate cancer, pancreatic cancer, cancer of the CNS, glioblastoma, a myeloproliferative disorder, atherosclerosis or lung fibrosis. 20. A method of inhibiting or modulating protein kinase activity in a biological sample comprising contacting a biological sample with the compound according to claim 1. 21. A method of inhibiting or modulating protein kinase activity in a biological sample comprising contacting a biological sample with the pharmaceutical composition according to claim 13. 22. The method of claim 20, wherein the protein kinases are receptor tyrosine kinases. 23. The method of claim 22, wherein the receptor tyrosine kinases are KDR and/or c-Met. 24. The method of claim 21, wherein the protein kinases are receptor tyrosine kinases. 25. The method of claim 24, wherein the receptor tyrosine kinases are KDR and/or c-Met.

Details for Patent 8,232,294

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-03-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-03-21
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	06/27/2003		2029-03-21
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2029-03-21